|
🐜
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
16 auth.
S. Gettinger,
L. Bazhenova,
C. Langer,
R. Salgia,
K. Gold,
R. Rosell,
A. Shaw,
G. Weiss,
M. Tugnait,
N. Narasimhan,
...
D. Dorer,
D. Kerstein,
V. Rivera,
T. Clackson,
F. Haluska,
D. Camidge
|
8 |
2016 |
8
🐜
|
|
🐜
|
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
21 auth.
M. Heinrich,
Robin L. Jones,
M. von Mehren,
P. Schöffski,
C. Serrano,
Yoon-Koo Kang,
P. Cassier,
O. Mir,
F. Eskens,
W. Tap,
...
P. Rutkowski,
S. Chawla,
J. Trent,
M. Tugnait,
E. Evans,
Tamieka Lauz,
T. Zhou,
M. Roche,
B. Wolf,
S. Bauer,
S. George
|
7 |
2020 |
7
🐜
|
|
🐜
|
Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.
27 auth.
Vincent Mascitti,
T. Maurer,
R. Robinson,
J. Bian,
Carine M. Boustany-Kari,
T. Brandt,
Benjamin M. Collman,
A. Kalgutkar,
Michelle K. Klenotic,
M. Leininger,
A. Lowe,
R. Maguire,
Victoria M. Masterson,
Z. Miao,
Emi Mukaiyama,
...
Jigna D. Patel,
J. Pettersen,
Cathy Préville,
Brian Samas,
Li She,
Z. Sobol,
C. Steppan,
Benjamin D. Stevens,
B. Thuma,
M. Tugnait,
Dongxiang Zeng,
T. Zhu
|
6 |
2011 |
6
🐜
|
|
🐜
|
Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects
9 auth.
Z. Miao,
G. Nucci,
N. Amin,
Raman K. Sharma,
Vincent Mascitti,
M. Tugnait,
...
A. Vaz,
Ernesto Callegari,
A. Kalgutkar
|
6 |
2013 |
6
🐜
|
|
🐜
|
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.
35 auth.
R. Kim,
D. Sarker,
T. Meyer,
T. Yau,
T. Macarulla,
Joong-Won Park,
S. Choo,
A. Hollebecque,
M. Sung,
Ho Yeong Lim,
V. Mazzaferro,
J. Trojan,
A. Zhu,
Jung‐Hwan Yoon,
Sunil Sharma,
...
Zhong‐Zhe Lin,
S. Chan,
S. Faivre,
L. Feun,
C. Yen,
J. Dufour,
D. Palmer,
J. Llovet,
Melissa Manoogian,
M. Tugnait,
Nicolas Stransky,
M. Hagel,
N. Kohl,
C. Lengauer,
C. Sherwin,
O. Schmidt-Kittler,
K. Hoeflich,
Hongliang Shi,
B. Wolf,
Yoon-Koo Kang
|
6 |
2019 |
6
🐜
|
|
🐜
|
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
18 auth.
D. DeAngelo,
D. Radia,
T. George,
W. Robinson,
A. Quiery,
M. Drummond,
P. Bose,
E. Hexner,
E. Winton,
H. Horny,
...
M. Tugnait,
O. Schmidt-Kittler,
E. Evans,
Hui-Min Lin,
B. Mar,
S. Verstovsek,
M. Deininger,
J. Gotlib
|
6 |
2021 |
6
🐜
|
|
🐜
|
Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus
12 auth.
A. Kalgutkar,
M. Tugnait,
T. Zhu,
Emi Kimoto,
Z. Miao,
Vincent Mascitti,
...
Xin Yang,
Beijing Tan,
R. Walsky,
J. Chupka,
B. Feng,
R. Robinson
|
6 |
2011 |
6
🐜
|
|
🦁
|
Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine.
M. Tugnait,
E. Hawes,
G. Mckay,
M. Eichelbaum,
K. Midha
|
5 |
1999 |
5
🦁
|
|
🐜
|
The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
10 auth.
Rena J. Eudy,
Vaishali Sahasrabudhe,
K. Sweeney,
M. Tugnait,
Amanda J. King-Ahmad,
Kristen E Near,
...
P. Loria,
M. Banker,
D. Piotrowski,
Carine M. Boustany-Kari
|
5 |
2011 |
5
🐜
|
|
🐜
|
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
12 auth.
S. Orena,
T. Maurer,
Li She,
Rena J. Eudy,
Vincent Bernardo,
Darla Dash,
...
P. Loria,
M. Banker,
M. Tugnait,
C. Okerberg,
Jessie Qian,
Carine M. Boustany-Kari
|
5 |
2013 |
5
🐜
|
